T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas ...

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders ...

I, a protein platform for reprogramming immune responses. A better understanding of its structure may help optimize designs for the platform, which can be used to develop cancer treatments by either ...

Trial reveals no survival benefit from autologous stem cell transplant for mantle cell lymphoma patients with undetectable ...

Nemtabrutinib is a small molecule commercialized by Merck, with a leading Phase III program in Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory Chronic Lymphocytic Leukemia (CLL).

diffuse large B-cell lymphoma, multiple myeloma, and follicular lymphoma. Intense global research is now exploring the clinical potential of CAR T-cell therapies beyond blood cancers, with therapies ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

Roche presents new and updated data for fixed-duration Columvi and Lunsumio at ASH 2024 meeting: Basel Wednesday, December 11, 2024, 11:00 Hrs [IST] Roche announced that new and u ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma compared with Rituxan alone.